1287262-18-3

Upstream product

• 1257865-15-8 5-(sec-butyl)-4-hydroxybenzene-1,3-dicarbaldehyde 
• 122-00-9 para-methylacetophenone 
• 89-72-5 2-sec-butylphenol 

Downstream Products

• 1262101-93-8 (E)-ethyl 8-sec-butyl-2-oxo-6-(3-oxo-3-p-tolylprop-1-enyl)-2H-chromene-3-carboxylate 
• 1361022-22-1 8-(3-oxo-3-p-tolylprop-1-enyl),10-sec-butyl-3,4-dihydro-2H,6H-3,6-epoxy-benzo[1,5]dioxocine 
• 1375171-77-9 (E)-2-sec-butyl-6-((1-propylamino)methylene)-4-((E)-3-oxo-3-p-tolylprop-1-enyl)cyclohexa-2,4-dienone 
• 1375171-75-7 (E)-2-sec-butyl-6-((ethylamino)methylene)-4-((E)-3-oxo-3-p-tolylprop-1-enyl)cyclohexa-2,4-dienone 
• 1375171-78-0 (E)-2-sec-butyl-4-((E)-3-oxo-3-p-tolylprop-1-enyl)-6-((phenylamino)methylene)cyclohexa-2,4-dienone 
• 1357475-89-8 ethyl 8-sec-butyl-2-oxo-6-(3-oxo-3-p-tolylprop-1-enyl)-2H-chromene-3-carboxylate 

Relevant academic research and scientific papers

COUMARIN-CHALCONES AS ANTICANCER AGENTS

The present invention relates to certain coumarin/chalcone compounds or a pharmaceutically acceptable salt thereof. The present invention particularly relates to the coumarin/chalcone compounds as anticancer agents useful for the treatment of cancer. The

In vitro and in vivo antifilarial activity evaluation of 3,6-epoxy [1,5]dioxocines: A new class of antifilarial agents

A series of 3,6-epoxy [1,5]dioxocines were synthesized and evaluated for their antifilarial activity against adult parasites of human lymphatic filarial parasite Brugia malayi (sub-periodic strain) in vitro. Out of these, six compounds (4a-f) possessed im

COUMARIN-CHALCONES AS ANTICANCER AGENTS

The present invention relates to certain coumarin/chalcone compounds or a pharmaceutically acceptable salt thereof. The present invention particularly relates to the coumarin/chalcone compounds as anticancer agents useful for the treatment of cancer. The

Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents

A series of coumarin-chalcone hybrids have been synthesized and evaluated for their in vitro cytotoxicity against a panel of four human cancer cell lines and normal fibroblasts (NIH3T3). Among 21 compounds screened, three compounds (23, 25 and 26) showed IC50 range from 3.59 to 8.12 μM. The most promising compound 26 showed around 30-fold more selectivity towards C33A (cervical carcinoma) cells over normal fibroblast NIH3T3 cells with an IC 50 value of 3.59 μM.